Preclinical and clinical trials of oncolytic vaccinia virus in cancer immunotherapy: a comprehensive review.

ABSTRACT: Oncolytic virotherapy has emerged as a promising treatment for human cancers owing to an ability to elicit curative effects via systemic administration. Tumor cells often create an unfavorable immunosuppressive microenvironment that degrade viral structures and impede viral replication; however, recent studies have established that viruses altered via genetic modifications can serve as effective oncolytic agents to combat hostile tumor environments. Specifically, oncolytic vaccinia virus (OVV) has gained popularity owing to its safety, potential for systemic delivery, and large gene insertion capacity. This review highlights current research on the use of engineered mutated viruses and gene-armed OVVs to reverse the tumor microenvironment and enhance antitumor activity in

SUBMITTER: Li M 

PROVIDER: S-EPMC10546091 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature